Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 152, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2022.113148
Keywords
Type 2 diabetes; Gut microbiota; Eubiosis; Dysbiosis
Funding
- Department of Biotechnology (DBT)
- Science and Engineering Research Board (SERB), Govt. of India
Ask authors/readers for more resources
This review provides an overview of the evidence and underlying mechanisms by which bioactive compounds modulate the gut microbiota for the prevention and management of type 2 diabetes mellitus.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia and insulin resistance. Gut microbiota (GM) are specific groups of microbes colonized in the gastrointestinal (GI) tract. They profoundly influence health, disease protection, and associated with metabolic activities, and play a vital role in the production of functional metabolites from dietary substances. Dysbiosis of GM has been linked to the onset of T2DM and can be altered to attain eubiosis by intervention with various nutritional bioactive compounds such as polyphenols, prebiotics, and probiotics. This review presents an overview of the evidence and underlying mechanisms by which bioactive compounds modulate the GM for the prevention and management of T2DM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available